Femara helps prevent the return of breast cancer

	Tweet

In more good news for women suffering from breast cancer a study by the the Swiss drugmaker Novartis has shown that their drug Femara benefits women with hormone-sensitive early breast cancer.

The drug company says that postmenopausal women who switched from a placebo to Femara experienced a 69-percent reduction in the risk of their breast cancer returning.

The new data has been presented at the 28th annual San Antonio Breast Cancer Symposium in Texas and is the first time that an aromatase inhibitor has shown a benefit in starting therapy up to five years after the end of standard Tamoxifen treatment.

RELATED STORIES:
Resistance to anti-estrogen therapy in breast cancer due to natural cell response   Chemotherapy-induced anemia increases risk of local breast cancer recurrence   Fear a Mammogram? Follow These Tips   Prolonged maternal separation increased breast cancer risk in neonatal mice   Screening Mammography in Elderly Patients Beneficial   Elevated-risk women refuse MRI breast cancer screening   Study Assesses Neuropathic Pain Risk for Breast Cancer Patients   Treating bone loss in breast cancer survivors   ‘Microtentacles’ on tumor cells appear to play role in how breast cancer spreads   Diabetes drug shows promise in reducing risk of cancer   Prevennia Supplement Blocks the Initiation of Breast Cell Mutations by Estrogens   Rate of Breast Cancer in Italy Significantly Higher than Previously Reported   K-State Research Team Investigates Mutated Gene’s Role in Breast Cancer   Avastin raises heart failure risk in breast cancer   Urine test may tell of breast cancer’s spread   A New Gamma Camera Technique for the Detection of Small Breast Tumors   Celldex breast cancer drug shrinks some tumors: study   Interval post-treatment mammogram not needed for breast cancer patients   Scientists uncover multiple faces of deadly breast cancer   Soy may prevent breast cancer, study hints   New Tool to Diagnose and Treat Breast Cancer   Low-dose radiation may raise breast cancer risk

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]